Guangzhou Huajin Pharmaceutical Technology Co., Ltd.-News

Stunning Breakthrough in Advanced HCC: SGN1 Extends Survival Beyond 50 Months in Patients After Second-Line Failure!

넶0 2025-07-03
Oncolytic Bacteria SalMet-Vec® Granted Orphan Drug Designation by U.S. FDA for Nasopharyngeal Carcinoma

넶42 2025-06-17
Joining Hands with the "Win-Win Enterprise Program" to Embark on a New Journey of Financial Empowerment for Pharmaceutical Innovation

넶35 2025-05-26
The oncolytic bacteria drug SalMet-Vec® has obtained the Orphan Drug Designation (ODD) from FDA for the treatment of pancreatic cancer

넶332 2025-01-08
Sinogen Pharmaceutical has been selected as a "Future Unicorn" innovative enterprise in Guangzhou for 3 consecutive years

넶204 2024-12-30

Position：Home > News

Press Releases
Industry Dynamics

Press Releases

——

Address：Room 101, 1st Floor, Building C5, Science and Technology Enterprise Accelerator, Huangpu District, Guangzhou Email : sinogen@sinogen.cc Service Time : Work days 9:00 ~ 17:00

About Us

Science&Prouduct

News

Contact Us

sinogen@sinogen.cc
Work days 9: 00 ~17: 00
Address：Room 101, 1st Floor, Building C5,
Science and Technology Enterprise Accelerator,
Huangpu District, Guangzhou

Investor Relations

Shareholder Information

Careers

Stunning Breakthrough in Advanced HCC: SGN1 Extends Survival Beyond 50 Months in Patients After Second-Line Failure!

Oncolytic Bacteria SalMet-Vec® Granted Orphan Drug Designation by U.S. FDA for Nasopharyngeal Carcinoma

Joining Hands with the "Win-Win Enterprise Program" to Embark on a New Journey of Financial Empowerment for Pharmaceutical Innovation

The oncolytic bacteria drug SalMet-Vec® has obtained the Orphan Drug Designation (ODD) from FDA for the treatment of pancreatic cancer

Sinogen Pharmaceutical has been selected as a "Future Unicorn" innovative enterprise in Guangzhou for 3 consecutive years